Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in
treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,
such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving carfilzomib, pomalidomide, and dexamethasone may work better in treating
patients with multiple myeloma.